Investor Relations

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

January Corporate Presentation

Stock Info
NASDAQVIRX

Recent News
Jan 4, 2022

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C....

Dec 16, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology...

Dec 13, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the presentation of new preclinical data on vecabrutinib, a...

View All

Events
Monday, January 10, 2022
7:00am EST
Monday, December 13, 2021
Monday, November 29, 2021 - Thursday, December 2, 2021

Conference Dates: November 29 – December 2, 2021
Presentation Available: November 22, 2021, at 10:00 AM ET

View All

Investor Contact

Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com